Canada and the US – the world is these Aussie medtechs’ oyster.
Sydney-based software solutions company Novari Health has signed a $19 million, five-year agreement with Nova Scotia Health, one of Canada’s largest providers of health services.
Novari’s surgical waitlist management system, referral central intake and medical imaging requisition management modules – all part of its Access to Care Software Platform – will be implemented across NSH’s 41 sites.
“The service-wide deployment of the Novari platform is a key piece of Nova Scotia’s healthcare technology modernisation program and initiatives to help improve access to care for patients and reduce waiting times,” said the company announcement.
“Novari Health’s single point of access, triaging, routing, and workflow software is the leading global system for hospitals, regions, and national health systems.
“Its capabilities include AI-enabled analytics to provide healthcare administrators, clinicians, and leadership with insight into the volume and waiting times for patients waiting for care, as well as providing real-time intelligence to drive continuous process improvement.
Novari Health partnered with Oracle Health (formerly Cerner) to provide enterprise referral and waiting list management technology for the One Person One Record (OPOR) modernisation project. OPOR is the largest healthcare transformation project in Nova Scotia’s history.
Lumos partners with MedPro
Melbourne-based point-of-care diagnostics company Lumos Diagnostics has joined forces with sales firm MedPro to market Lumos’ FebriDx assay across the US.
FebriDx is a rapid POC test that aids in differentiating between bacterial and non-bacterial infections.
MedPro will provide customer lead generation, sales revenue, and customer training for FebriDx across the US hospital environment and government agencies such as the Department of Defense, Veterans Affairs, Department of Health and Human Services, Indian Health Services and the Federal Bureau of Prisons.
MedPro also services physician offices, ambulatory surgical centres, skilled nursing facilities and home health agencies.
“We are thrilled to be working alongside MedPro to bring our products to the US market,” said Lumos CEO Doug Ward.
ImmVirX wins $5m tax refund
Melbourne life sciences company ImmVirX has received a $5.08 million research and development tax refund as part of the federal government’s R&D incentive program.
The refund received by ImmVirX will contribute to the development of its investigational products IVX037 and IVX055 in various combination settings including with immune checkpoint inhibitors and CAR-T therapies.
IVX037 is being assessed in combination with the immune checkpoint inhibitor, sintilimab across multiple clinical sites in Australia.